PL3248597T3 - Środek terapeutyczny na niedosłuch czuciowo-nerwowy - Google Patents

Środek terapeutyczny na niedosłuch czuciowo-nerwowy

Info

Publication number
PL3248597T3
PL3248597T3 PL16740038.1T PL16740038T PL3248597T3 PL 3248597 T3 PL3248597 T3 PL 3248597T3 PL 16740038 T PL16740038 T PL 16740038T PL 3248597 T3 PL3248597 T3 PL 3248597T3
Authority
PL
Poland
Prior art keywords
therapeutic agent
hearing loss
sensorineural hearing
sensorineural
loss
Prior art date
Application number
PL16740038.1T
Other languages
English (en)
Inventor
Makoto Hosoya
Masato Fujioka
Hideyuki Okano
Kaoru Ogawa
Tatsuo Matsunaga
Original Assignee
Keio University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keio University filed Critical Keio University
Publication of PL3248597T3 publication Critical patent/PL3248597T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL16740038.1T 2015-01-19 2016-01-13 Środek terapeutyczny na niedosłuch czuciowo-nerwowy PL3248597T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015007849 2015-01-19
PCT/JP2016/050861 WO2016117431A1 (ja) 2015-01-19 2016-01-13 内耳性難聴治療薬

Publications (1)

Publication Number Publication Date
PL3248597T3 true PL3248597T3 (pl) 2024-06-24

Family

ID=56416978

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16740038.1T PL3248597T3 (pl) 2015-01-19 2016-01-13 Środek terapeutyczny na niedosłuch czuciowo-nerwowy

Country Status (9)

Country Link
US (2) US11058669B2 (pl)
EP (2) EP3248597B1 (pl)
JP (2) JP6716139B2 (pl)
DK (1) DK3248597T3 (pl)
ES (2) ES2928593T3 (pl)
FI (1) FI3248597T3 (pl)
PL (1) PL3248597T3 (pl)
PT (1) PT3248597T (pl)
WO (1) WO2016117431A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101785455B1 (ko) * 2016-03-16 2017-11-20 전남대학교산학협력단 귀리 추출물을 유효성분으로 포함하는 난청의 예방 또는 치료용 약제학적 조성물
KR102426447B1 (ko) * 2017-05-26 2022-07-29 카이트 파마 인코포레이티드 배아 중간엽 전구 세포를 제조하고 사용하는 방법
JP6999896B2 (ja) 2017-09-21 2022-01-19 学校法人慶應義塾 音響外傷難聴モデル動物の作製方法及びそれにより作製される音響外傷難聴モデル動物
CN108310386A (zh) * 2018-04-09 2018-07-24 南方医科大学 mTOR信号通路抑制剂在制备预防或治疗非遗传性听力障碍药物中的用途
JP2023106640A (ja) * 2020-06-09 2023-08-02 株式会社オトリンク 内耳有毛細胞の製造方法、薬剤の評価方法、及び細胞分化誘導用組成物
WO2022225359A1 (ko) * 2021-04-23 2022-10-27 연세대학교 산학협력단 오토파지 활성화제를 유효성분으로 포함하는 비증후군성 상염색제-우성 난청의 예방 또는 치료용 조성물
WO2024144371A1 (en) * 2022-12-30 2024-07-04 Arbormed Co., Ltd. Pharmaceutically active compounds, compositions, and methods for modulating pendrin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3963495B2 (ja) 1995-05-22 2007-08-22 生化学工業株式会社 アポトーシス惹起抑制剤
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
CA2383451A1 (en) 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. 28-epirapalogs
DE60142677D1 (de) 2000-01-14 2010-09-09 Univ Pennsylvania O-methylierte rapamycinderivate zur milderung oder vermeidung lymphoproliferativer erkrankungen
JP2004123713A (ja) 2002-08-05 2004-04-22 Mitsubishi Pharma Corp 突発性難聴の予防及び/又は治療のための医薬
JP2004099537A (ja) 2002-09-10 2004-04-02 Sanwa Kagaku Kenkyusho Co Ltd 難聴疾患の予防又は治療剤
WO2005009287A2 (en) * 2003-07-21 2005-02-03 University Of Maryland, Baltimore Drug delivery to the inner ear and methods of using same
KR20080018874A (ko) 2005-04-27 2008-02-28 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 인간 질병과 관련된 돌연변이 단백질의 분해 촉진을 위한물질 및 방법
RU2010104916A (ru) * 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
AU2008254500B2 (en) 2007-05-17 2014-01-23 Atnx Spv, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
CN102099013A (zh) 2008-07-14 2011-06-15 奥德纳米有限公司 用于治疗耳部病症的控制释放凋亡调节组合物和方法
KR20130128018A (ko) * 2009-04-10 2013-11-25 하이얀 치 새로운 노화 방지 물질 및 그 확인 방법

Also Published As

Publication number Publication date
US11013725B2 (en) 2021-05-25
WO2016117431A1 (ja) 2016-07-28
ES2978203T3 (es) 2024-09-06
EP3295939B1 (en) 2022-09-21
EP3295939A1 (en) 2018-03-21
DK3248597T3 (da) 2024-04-08
PT3248597T (pt) 2024-03-25
EP3248597B1 (en) 2024-03-13
FI3248597T3 (fi) 2024-04-17
US20170340586A1 (en) 2017-11-30
US11058669B2 (en) 2021-07-13
EP3248597A1 (en) 2017-11-29
ES2928593T3 (es) 2022-11-21
JP2017200923A (ja) 2017-11-09
JP6716139B2 (ja) 2020-07-01
JPWO2016117431A1 (ja) 2017-11-02
EP3248597A4 (en) 2018-10-10
US20170333403A1 (en) 2017-11-23
JP6708346B2 (ja) 2020-06-10

Similar Documents

Publication Publication Date Title
HK1256383A1 (zh) 治療劑
AU367792S (en) Loudspeaker
EP3199628A4 (en) Cytotoxicity-inducing therapeutic agent
GB201509893D0 (en) Therapeutic agents
PL3373882T3 (pl) Izolator pacjenta
GB201517263D0 (en) Therapeutic agents
PL3248597T3 (pl) Środek terapeutyczny na niedosłuch czuciowo-nerwowy
GB201509283D0 (en) Hearing aid
DK3470112T3 (en) Cochlear implantat
SI3254474T1 (sl) Elektroakustični implantat
HK1245639A1 (zh) 纖維化病治療劑
GB201518214D0 (en) Loudspeaker
GB201516297D0 (en) Loudspeaker
GB201509885D0 (en) Therapeutic agents
GB201509888D0 (en) Therapeutic agents
GB2537353B (en) Earphone
GB201717279D0 (en) Identifier
EP3305311A4 (en) Brain function-protecting agent
PL3306953T3 (pl) Głośnik
GB201513299D0 (en) Therapeutic agents
GB2546067B (en) Loudspeaker
GB201521767D0 (en) Therapeutic agents
AU201611783S (en) Loudspeaker
GB201517264D0 (en) Therapeutic agents
GB201501003D0 (en) In-ear monitor